Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 11/20 | 0.45 |
| ▸ | PARP15 | Q460N3 | 6/20 | 0.45 |
| ▸ | PARP14 | Q460N5 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | AKT2 | P31751 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6321984 | 1.00 | PARP1 (0.45) | PARP1PARP10PARP15PARP14MEN1 | |
| SCHEMBL6319477 | 0.90 | GSK3B (0.47) | MEN1KMT2A | |
| SCHEMBL6319473 | 0.90 | GSK3B (0.47) | MEN1KMT2A | |
| SCHEMBL6326901 | 0.89 | PLAU (0.40) | AKT2PDPK1KDRIDO1 | |
| SCHEMBL6318906 | 0.88 | PDPK1 (0.39) | MEN1KMT2AAKT2PDPK1KDR | |
| SCHEMBL6322523 | 0.88 | KDR (0.44) | PARP1KMT2AKDRIDO1 | |
| SCHEMBL6322520 | 0.88 | KDR (0.44) | PARP1KMT2AKDRIDO1 | |
| SCHEMBL3157766 | 0.88 | PLAU (0.46) | PARP1PARP10PARP15PARP14MEN1 | |
| SCHEMBL3157774 | 0.88 | PLAU (0.46) | PARP1PARP10PARP15PARP14MEN1 | |
| SCHEMBL6320960 | 0.87 | PDPK1 (0.46) | MEN1KMT2APDPK1KDRIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855710-B2 | Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-25 | — | — | US | disclosed |
| EP-1115704-B1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | CDK1, CDK2, CDK3 | PARP1 1117/4885PARP10 1656/4885PARP15 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.